Other EGFR therapies are associated with AEs that have not been reported with amivantamab monotherapy, such as anemia, aminotransferase elevations, neutropenia, thrombocytopenia with gefitinib, and prolonged QT interval with osimertinib.9,12,15 When amivantamab is combined with additional drugs in combination regimens, other AEs, as discussed in the following section, may occur. Here, EGFR is linked to neutropenia.